Cystic
fibrosis (CF) is a genetic disorder that usually affects the lungs
and may also affect the pancreas, kidneys, liver, and intestine.
Long-term repercussions including difficulty in breathing and
coughing as a result of recurrent lung infections can be seen in CF.
Some of the other signs and symptoms include sinus infections, poor
growth, infertility in males, fatty stool, and guild of the fingers
and toes. Different individuals may have diverse degrees of symptoms.
CF is chiefly inherited as an autosomal recessive gene. It is
triggered by mutations in both the copies of the gene for CFTR or
cystic fibrosis transmembrane conductance regulator protein.
Individuals with a single copy are carriers. Cystic fibrosis
transmembrane conductance regulator protein is involved in the
production of digestive fluids, mucus, and sweat. When the protein is
not functional, secretions otherwise thin become thick. The ailment
is mostly diagnosed by genetic testing and sweat test.
Get
In-Depth Sample Copy of Research @
https://www.coherentmarketinsights.com/insight/request-sample/236
Over
the last few years, advancements in technology have resulted in a
shift in research and development towards treatments that target the
fundamental cause of the disease by targeting the CFTR function.
Moreover, there is an affinity towards licensing the products, and
for that reason alliances are being made by a number of biotechnology
and pharmaceutical manufacturers, since the majority of the
treatments for cystic fibrosis are developed by smaller
manufacturers. The increase in licensing activity along with the rise
in the number of new partnerships will encourage the smaller
companies to continue their research work thereby giving a positive
momentum to the cystic fibrosis market.
In
spite of significant advancement in cystic fibrosis therapeutics,
individuals suffering from CF face significant unmet needs owing to
the deficiency of restorative therapies, inadequate choice of
mucolytic treatments, and the unvarying fight alongside severe lung
infection that needs the expansion of novel antibiotics. These
factors are likely to drive the growth of the cystic fibrosis market
during the forecast period.
High
prevalence of genetic diseases including CF will drive the overall
cystic fibrosis market
According
to Netwellness, a community service provider, 3 to 4% of the babies
are born with genetic disorders. This number is poised to rise in the
coming years, especially in the emerging economies of Asia pacific
such as China and India owing to high birth rate observed in these
regions. As the number of cases of CF rises, so will the demand for
CF treatment, thereby augmenting the growth of the overall cystic
fibrosis market during the forecast period.
On
the basis of geography North America held the maximum market share in
the cystic fibrosis market globally. Constructive and favorable
regulations and policies as well as high availability of
sophisticated healthcare facilities and rising approvals of drugs for
treating CF are likely to propel the growth of the cystic fibrosis
industry in this region.
Competitor
Landscape
Some
of the key players operating in the global cystic fibrosis market are
AbbVie, Inc., Aradigm, Aurora Biosciences, Bayer AG, Demegen, EryDel,
Genentech, Inc., InDex Pharmaceuticals, ManRos Therapeutics, Novartis
AG, Polydex Pharmaceuticals, and F. Hoffmann-La Roche AG.
Cystic
fibrosis market Taxonomy -
On
the basis of therapy type, the global market is classified into:
-
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators
-
Protein Transcription Modulators
-
Pancreatic Enzyme Products (PEP)
-
Other therapies
Browse
Full Report @
https://www.coherentmarketinsights.com/ongoing-insight/cystic-fibrosis-market-236
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment